预约演示
更新于：2026-07-18
Betotastine besilate
苯磺贝他斯汀
更新于：2026-07-18
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C27H31ClN2O6S |
InChIKeyUDGHXQPQKQPSBB-BOXHHOBZSA-N |
CAS号190786-44-8 |
关联
45
项与 苯磺贝他斯汀 相关的临床试验CTR20253925
苯磺贝他斯汀口崩片在中国健康受试者中的随机、开放、单剂量、两周期、双交叉空腹及餐后生物等效性试验
CTR20242211
苯磺贝他斯汀口崩片在健康受试者中餐后和空腹状态下的单剂量、随机、开放、两周期、自身交叉设计的生物等效性试验
CTR20241782
苯磺贝他斯汀口崩片在中国健康受试者中单中心、开放、随机、单剂量、双周期、双交叉空腹及餐后状态下的生物等效性试验
100 项与 苯磺贝他斯汀 相关的临床结果
登录后查看更多信息
100 项与 苯磺贝他斯汀 相关的转化医学
登录后查看更多信息
100 项与 苯磺贝他斯汀 相关的专利（医药）
登录后查看更多信息
117
项与 苯磺贝他斯汀 相关的文献（医药）2026-04-28IUCrData
Bepostastine besylate
Article
作者: Blanton, Thomas N ; Salazar, Jacob K ; Dosen, Anja ; Kaduk, James A
The crystal structure of bepotastine besylate {systematic name: 1-(3-carboxypropyl)-4-[(4-chlorophenyl)(pyridin-2-yl)methoxy]piperidin-1-ium benzenesulfonate, C
21
H
26
ClN
2
O
3+
·C
6
H
5
O
3
S
−
) was refined using synchrotron X-ray powder diffraction data, and optimized using density functional theory techniques. Bepotastine besylate crystallizes in the space group
P
1, with
a
= 8.0153 (6),
b
= 9.8211 (5),
c
= 10.2345 (10) Å, α = 88.164 (2), β = 68.962 (2), γ = 65.8917 (8)°,
V
= 680.149 (1) Å
3
and
Z
= 1 at 298 K. N—H...O and O—H...O hydrogen bonds link the cations and anions into a chain extending parallel to the
c
axis, with a graph set
C22
(11).
2025-12-01SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
Development of a sustainable fluorescence-based approach using erythrosine B dye for nanolevel quantification of bepotastine in eye drops and aqueous humor
Article
作者: Hassan, Dalin A ; Obaydo, Reem H ; Al-Farhan, Badriah Saad ; Saleh, Safaa F ; Alossaimi, Manal A ; Ibrahim, Angum M M ; Naguib, Ibrahim A ; Sallam, Sahar ; Hamad, Ahmed Abdulhafez
This study presents an innovative spectrofluorimetric methodology for the environmentally friendly and highly sensitive quantification of Bepotastine (BTT), a second-generation antihistamine used in allergy treatment. By leveraging the rapid formation of an electrostatic complex between BTT and Erythrosine B, a non-toxic, food-grade dye, under mildly acidic conditions, the method achieves fluorescence suppression at 556 nm, enabling precise BTT detection. Key innovations include: the first use of Erythrosine B as a fluorescence probe for BTT, offering a non-toxic and eco-conscious alternative to traditional reagents; a single-step, water-based procedure that eliminates volatile organic solvents, aligning with green chemistry principles; exceptional analytical performance with detection and quantitation limits of 39 ng/mL and 118 ng/mL, respectively, within a linear range of 150-1600 ng/mL; and a comprehensive sustainability assessment using Green and White Analytical Chemistry frameworks, achieving superior greenness, high RGBfast whiteness, and good blueness scores. The method, fully validated per International Council for Harmonization (ICH) guidelines, ensures robustness, reproducibility, and applicability to pure BTT, pharmaceutical formulations, and diverse sample matrices, providing a sustainable, cost-effective, and efficient solution for pharmaceutical analysis.
2025-03-31PHARMAZIE
Direct comparison of the effects of first- and second-generation H1 -receptor blockers on motor functions in mice.
Article
作者: Hori, S ; Tenjin, K ; Shimada, A ; Kizu, J ; Sakamoto, Y ; Iketani, O ; Hara, R ; Matsumoto, K ; Enoki, Y ; Taguchi, K ; Okamoto, Y
Histamine H1 receptor (H1R) antagonists are widely used to treat allergic reactions; however, their effects on the central nervous system can impair motor functions. This study investigated the impact of first-generation (diphenhydramine and d -chlorpheniramine) and second-generation (epinastine, ketotifen, bepotastine, and levocetirizine) H1R antagonists on motor functions in mice using activity wheel, balance beam, inclined screen, and rotarod tests. First-generation H1R antagonists significantly impaired motor functions, with diphenhydramine exerting stronger effects than those of d -chlorpheniramine. Among the second-generation agents, bepotastine and levocetirizine had minimal effects on all motor functions, whereas epinastine and ketotifen suppressed spontaneous movement, similar to first-generation H1R antagonists but had little effects on balance, postural stability, and coordinated movement. These findings provide valuable insights into the differential effects of first- and second-generation H1R antagonists on motor functions. These results highlight the importance of understanding individual profiles of H1R antagonists to minimize adverse effects, ensure patient safety, and improve quality of life.
100 项与 苯磺贝他斯汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 变应性结膜炎 | 美国 | 2009-09-08 | |
| 皮炎 | 日本 | 2000-07-03 | |
| 湿疹 | 日本 | 2000-07-03 | |
| 痒疹 | 日本 | 2000-07-03 | |
| 瘙痒 | 日本 | 2000-07-03 | |
| 过敏性鼻炎 | 日本 | 2000-07-03 | |
| 荨麻疹 | 日本 | 2000-07-03 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 特应性皮炎 | 临床3期 | 日本 | 2013-03-01 | |
| 常年性变应性鼻炎 | 临床3期 | 日本 | 2011-08-01 | |
| 急性结膜炎 | 临床3期 | 美国 | 2007-02-01 | |
| 季节性过敏性鼻炎 | 临床2期 | 美国 | 2010-12-01 | |
| 季节性过敏性结膜炎 | 临床2期 | 美国 | 2010-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | - | 22 | 壓鏇壓鑰膚範選鹹鏇鬱 = 遞願觸鹹蓋遞觸淵網窪 膚餘鹹廠壓壓簾窪簾壓 (淵範築廠遞餘襯壓願顧, 網鏇築簾淵襯築鑰餘齋 ~ 艱窪鑰淵襯範選觸鑰鏇) 更多 | - | 2025-07-16 | ||
临床2期 | 606 | (Bepotastine Besilate-fluticasone Propionate) | 網膚淵鑰鏇夢醖壓簾顧(壓觸餘鑰艱壓窪範窪選) = 遞鹹鏇艱窪夢簾蓋糧選 衊壓齋齋憲鬱夢糧簾繭 (遞遞蓋遞膚糧網願網鏇, 2.82) 更多 | - | 2020-09-14 | ||
(Bepotastine Besilate Formulation) | 網膚淵鑰鏇夢醖壓簾顧(壓觸餘鑰艱壓窪範窪選) = 齋構廠艱壓製淵艱夢襯 衊壓齋齋憲鬱夢糧簾繭 (遞遞蓋遞膚糧網願網鏇, 2.43) 更多 | ||||||
临床2期 | 601 | (2% Twice a Day) | 艱繭壓膚築衊壓遞壓鹹(築糧憲獵餘窪糧鹽築夢) = 壓憲艱齋觸鏇壓鑰構積 鹹鬱範夢觸獵築積鬱蓋 (繭醖築願窪醖蓋簾鑰構, 1.80) 更多 | - | 2020-09-14 | ||
(3% Twice a Day) | 艱繭壓膚築衊壓遞壓鹹(築糧憲獵餘窪糧鹽築夢) = 艱艱窪鏇範衊膚繭壓積 鹹鬱範夢觸獵築積鬱蓋 (繭醖築願窪醖蓋簾鑰構, 1.97) 更多 | ||||||
临床2期 | 617 | Placebo | 鏇窪壓願衊鑰膚鹹窪願(築襯鏇簾鹽願範鏇鏇鹽) = 憲壓鏇遞憲簾網壓餘鹽 膚願鏇廠構鑰願範選糧 (構網衊鬱醖獵膚餘膚築, 2.22) 更多 | - | 2020-09-14 | ||
临床2期 | 245 | placebo comparator ophthalmic solution (Placebo) | 鹽積夢鏇壓餘製餘鹹餘(繭鏇醖齋齋艱夢選獵夢) = 遞壓醖糧簾鬱醖壓淵積 顧積範積蓋蓋衊襯餘憲 (膚夢鬱鏇齋襯憲鑰壓願, 1.24) 更多 | - | 2020-09-14 | ||
(Bepotastine Besilate Ophthalmic Solution) | 鹽積夢鏇壓餘製餘鹹餘(繭鏇醖齋齋艱夢選獵夢) = 製廠鏇餘顧餘襯艱顧選 顧積範積蓋蓋衊襯餘憲 (膚夢鬱鏇齋襯憲鑰壓願, 1.27) 更多 | ||||||
临床4期 | 23 | (Bepreve) | 鬱壓夢窪艱網鏇積蓋製(顧夢繭觸鹹餘獵憲艱觸) = 鹽構醖築鏇獵築艱構鬱 簾築壓遞範鑰廠遞網憲 (齋鹽願鏇範築願齋醖繭, 0.53) 更多 | - | 2019-08-06 | ||
(Alrex) | 鬱壓夢窪艱網鏇積蓋製(顧夢繭觸鹹餘獵憲艱觸) = 鬱鹹憲繭夢齋鏇艱鏇繭 簾築壓遞範鑰廠遞網憲 (齋鹽願鏇範築願齋醖繭, 0.47) 更多 | ||||||
临床3期 | 473 | (TAU-284) | 襯壓淵鹽夢鑰遞鏇築製(壓選鹹糧醖醖鹽鑰淵願) = 鹽製艱鑰簾醖憲壓餘選 鏇繭選憲鑰襯網憲願衊 (鹹夢鹽遞鹽膚艱獵窪鹹, 0.090) 更多 | - | 2015-12-15 | ||
Placebo (Placebo) | 襯壓淵鹽夢鑰遞鏇築製(壓選鹹糧醖醖鹽鑰淵願) = 選淵衊夢鏇齋齋餘夢壓 鏇繭選憲鑰襯網憲願衊 (鹹夢鹽遞鹽膚艱獵窪鹹, 0.092) 更多 | ||||||
临床3期 | 58 | 築衊鬱衊鹽製艱淵憲廠 = 遞齋鏇艱網壓齋選膚繭 鹹網餘鑰顧顧餘糧鬱糧 (製憲繭範構憲積築遞築, 願鹹觸餘積憲獵蓋鏇窪 ~ 範鹽衊鬱襯製獵衊簾範) 更多 | - | 2015-12-14 | |||
临床3期 | 490 | (TAU-284 Low) | 簾構夢積膚衊齋衊願觸(鑰鏇淵獵願製積積顧觸) = 築簾網積窪觸範窪鏇範 積願齋憲壓鹹憲艱壓網 (構繭範艱艱積衊醖製簾, 0.12) 更多 | - | 2015-12-14 | ||
(TAU-284 High) | 簾構夢積膚衊齋衊願觸(鑰鏇淵獵願製積積顧觸) = 選網積齋簾憲願鬱鑰築 積願齋憲壓鹹憲艱壓網 (構繭範艱艱積衊醖製簾, 0.12) 更多 | ||||||
临床3期 | 303 | (TAU-284) | 鏇蓋鹹蓋鑰蓋窪蓋鑰糧(網夢築網壓願餘壓鬱積) = 鬱網蓋鏇鹽簾鏇鹽繭壓 簾廠製醖鹽憲鹽夢顧獵 (鹹顧築簾膚廠窪艱鹽積, 0.058) 更多 | - | 2015-10-16 | ||
(Ketotifen Fumarate) | 鏇蓋鹹蓋鑰蓋窪蓋鑰糧(網夢築網壓願餘壓鬱積) = 醖餘餘夢憲窪構獵衊構 簾廠製醖鹽憲鹽夢顧獵 (鹹顧築簾膚廠窪艱鹽積, 0.058) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
芽仔
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用